Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Blaze Bioscience and Fred Hutchinson Cancer Research Center Collaborate

Published: Thursday, July 04, 2013
Last Updated: Thursday, July 04, 2013
Bookmark and Share
Collaboration leverages the Hutchinson Center’s research excellence with Blaze drug development expertise.

Blaze Bioscience, Inc. and Fred Hutchinson Cancer Research Center announced a collaboration and option agreement to support the Hutchinson Center’s Optides Discovery Program and advance drug candidates identified using the platform.

Optides, short for “optimized peptides,” are tiny molecules derived from natural organisms such as scorpions, violets and sunflowers. Optides can be instructed to bind to particular kinds of cancer cells, disabling only those cells. They also can be attached to chemotherapy drugs, transforming them into precision therapies that spare healthy cells.

Under the terms of the agreement, Blaze will provide development and commercialization guidance, as well as access to Blaze technology, for optide drug candidates during the discovery phase at the Hutchinson Center. Blaze has the option to exclusively license commercial rights to optide drug candidates that achieve certain criteria. In addition to technology access and support, the Hutchinson Center has received an additional equity stake in Blaze and will receive further payments on each product candidate optioned by Blaze. Any optide candidates not optioned by Blaze will belong fully to the Hutchinson Center including any intellectual property developed or provided by Blaze in the discovery phase for that optide candidate.

Blaze’s first development candidate, BLZ-100, is based on the first optide discovered by the Hutchinson Center. BLZ-100 is a variant of a peptide called chlorotoxin, which was originally derived from scorpion venom. This optide forms the backbone of the Tumor Paint technology previously licensed by Blaze.

“Collaborating on the Optides Program with the Hutchinson Center is a natural extension of our pipeline and utilizes our combined expertise,” said Heather Franklin, co-founder, president and chief executive officer of Blaze. “Our Tumor Paint technology program has maintained its aggressive schedule to advance BLZ-100 from license to clinic in just two years. Helping the Hutchinson Center quickly advance additional optide product candidates with efficient technology transfer followed by rapid entry into the clinic benefit both the Hutchinson Center and Blaze, but more importantly, may ultimately benefit patients.”

“We are pleased to establish this collaboration with Blaze. It is structured to efficiently match the Hutchinson Center’s superb discovery science with Blaze’s industry expertise in drug selection and peptide drug development in efforts to speed the transfer of Hutchinson Center optides discoveries to the clinic,” said Ulrich Mueller, vice president of Industry Relations and Clinical Research Support at the Hutchinson Center. “This will further the Hutchinson Center’s overarching mission to eliminate cancer and related diseases as causes of human suffering and death.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!